Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  


Glenmark Pharma Plunges 10%; BSE HEALTHCARE Index Up 0.0%
Tue, 12 Nov 9:14

Glenmark Pharma Plunges 10%; BSE HEALTHCARE Index Up 0.0%Image source: bluebay2014/www.istockphoto.com

Glenmark Pharma share price has plunged 10% and is presently trading at Rs 1,634.7.

Meanwhile, the BSE HEALTHCARE index is at 43,479.0 .

Among the top losers in the BSE HEALTHCARE index today are LAURUS LABS (down 2.6%) and APOLLO HOSPITALS (down 1.9%).

Procter & Gamble Health (up 2.8%) and FDC (up 2.6%) are among the top gainers today.

Over the last one year, Glenmark Pharma has moved up from Rs 785.7 to Rs 1,634.7, registering a gain of Rs 849.0 (up 108.1%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,646.0 to 43,479.0, registering a gain of 51.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 203.1%), SUVEN PHARMACEUTICALS (up 116.7%) and Glenmark Pharma (up 108.1%).

For Investors: Our Big Prediction

What About the Benchmark Indices?

The BSE Sensex is at 79,658.2 (up 0.2%).

The top gainers among the BSE Sensex today are Tata Steel (up 1.3%) and HCl Tech. (up 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 24,225.8 (up 0.4%). Hindalco and ONGC are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,975.6 to 79,658.2, registering a gain of 14,682.5 points (up 22.6%).

Glenmark Pharma Financial Update...

Glenmark Pharma net profit grew 803.0% YoY to Rs 3,402 million for the quarter ended June 2024, compared to a profit of Rs 377 million a year ago. Net sales rose 6.9% to Rs 32,442 million during the period as against Rs 30,361 million in April-June 2023.

For the year ended March 2024, Glenmark Pharma reported 1944.2% decrease in net profit to Rs -18,309 million compared to net loss of Rs 896 million during FY23. Revenue of the company grew 2.0% to Rs 118,131 million during FY24.

The current Price to earnings ratio of Glenmark Pharma, based on rolling 12 month earnings, stands at -30.2.


Equitymaster requests your view! Post a comment on "Glenmark Pharma Plunges 10%; BSE HEALTHCARE Index Up 0.0%". Click here!